文献速递脑血管病神经重症与神经感染

抗凝逆转时间与脑出血后结局的关系

Time to Anticoagulation Reversal and Outcomes After Intracerebral Hemorrhage.
PubMed 文献 · JAMA Neurol · 2024-02-09

该队列研究利用美国心脏协会「遵循指南-卒中」登记数据,纳入2015至2021年465家美国医院内发病24小时内就诊的抗凝相关脑出血患者。在5224例有流程时间记录并接受逆转治疗的患者中,中位门-治疗时间为82分钟,门-治疗时间≤60分钟与院内死亡及出院转临终关怀复合结局降低相关(校正OR 0.82,95%CI 0.69-0.99),但功能结局无差异。

要点

  • 抗凝相关脑出血患者中78.7%接受了逆转治疗。
  • 门-治疗时间≤60分钟与死亡及出院转临终关怀复合结局降低相关(校正OR 0.82)。
  • 门-治疗时间≤60分钟与功能结局(改良Rankin量表0-3分)无显著差异。

核心结论

  • 在美国参与「遵循指南-卒中」的医院中,更早的抗凝逆转与脑出血患者生存改善相关。
  • 这些发现支持加紧努力加速此类破坏性卒中患者的评估和治疗。

研究设计与样本

  • 队列研究,使用美国心脏协会「遵循指南-卒中」质量改进登记数据。
  • 纳入2015至2021年465家美国医院内发病24小时内就诊的脑出血患者。
  • 数据分析时间为2023年1月至9月。
  • 共9492例抗凝相关脑出血且记录逆转干预状态的患者,其中4232例(44.6%)为女性,中位(IQR)年龄77(68-84)岁。

主要发现

  • 7469例(78.7%)接受了逆转治疗,其中华法林服用者4616/5429例(85.0%),非维生素K拮抗剂口服抗凝药服用者2856/4069例(70.2%)。
  • 5224例接受逆转干预且有流程时间记录的患者中,中位(IQR)发病-治疗时间232(142-482)分钟,中位(IQR)门-治疗时间82(58-117)分钟,门-治疗时间≤60分钟者1449例(27.7%)。
  • 门-治疗时间≤60分钟与院内死亡及出院转临终关怀复合结局降低相关(校正OR 0.82;95%CI 0.69-0.99)。
  • 门-治疗时间≤60分钟与功能结局(改良Rankin量表评分0-3分)无显著差异(校正OR 0.91;95%CI 0.67-1.24)。
  • 与门-治疗时间≤60分钟相关的因素包括白人种族、较高收缩压和较低卒中严重程度。

临床怎么用

  • 原文结论指出这些发现支持加紧努力加速此类卒中患者的评估和治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Intracerebral hemorrhage (ICH) is the deadliest stroke subtype, and mortality rates are especially high in anticoagulation-associated ICH. Recently, specific anticoagulation reversal strategies have been developed, but it is not clear whether there is a time-dependent treatment effect for door-to-treatment (DTT) times in clinical practice. OBJECTIVE: To evaluate whether DTT time is associated with outcome among patients with anticoagulation-associated ICH treated with reversal interventions. DESIGN, SETTING, AND PARTICIPANTS: This cohort study used data from the American Heart Association Get With The Guidelines-Stroke quality improvement registry. Patients with ICH who presented within 24 hours of symptom onset across 465 US hospitals from 2015 to 2021 were included. Data were analyzed from January to September 2023. EXPOSURES: Anticoagulation-associated ICH. MAIN OUTCOMES AND MEASURES: DTT times and outcomes were analyzed using logistic regression modeling, adjusted for demographic, history, baseline, and hospital characteristics, with hospital-specific random intercepts to account for clustering by site. The primary outcome of interest was the composite inpatient mortality and discharge to hospice. Additional prespecified secondary outcomes, including functional outcome (discharge modified Rankin Scale score, ambulatory status, and discharge venue), were also examined. RESULTS: Of 9492 patients with anticoagulation-associated ICH and documented reversal intervention status, 4232 (44.6%) were female, and the median (IQR) age was 77 (68-84) years. A total of 7469 (78.7%) received reversal therapy, including 4616 of 5429 (85.0%) taking warfarin and 2856 of 4069 (70.2%) taking a non-vitamin K antagonist oral anticoagulant. For the 5224 patients taking a reversal intervention with documented workflow times, the median (IQR) onset-to-treatment time was 232 (142-482) minutes and the median (IQR) DTT time was 82 (58-117) minutes, with a DTT time of 60 minutes or less in 1449 (27.7%). A DTT time of 60 minutes or less was associated with decreased mortality and discharge to hospice (adjusted odds ratio, 0.82; 95% CI, 0.69-0.99) but no difference in functional outcome (ie, a modified Rankin Scale score of 0 to 3; adjusted odds ratio, 0.91; 95% CI, 0.67-1.24). Factors associated with a DTT time of 60 minutes or less included White race, higher systolic blood pressure, and lower stroke severity. CONCLUSIONS AND RELEVANCE: In US hospitals participating in Get With The Guidelines-Stroke, earlier anticoagulation reversal was associated with improved survival for patients with ICH. These findings support intensive efforts to accelerate evaluation and treatment for patients with this devastating form of stroke.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Sheth KN, Solomon N, Alhanti B, et al. Time to Anticoagulation Reversal and Outcomes After Intracerebral Hemorrhage. JAMA Neurol. 2024. PMID: 38335064. doi:10.1001/jamaneurol.2024.0221

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。